Test Code ALPGP Alport Syndrome Gene Panel, Varies
Ordering Guidance
Customization of this panel and single gene analysis for any gene present on this panel are available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.
Targeted testing for familial variants (also called site-specific or known mutations testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.
Shipping Instructions
Specimen preferred to arrive within 96 hours of collection.
Specimen Required
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Container/Tube:
Preferred: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Any anticoagulant
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Stability Information: Ambient (preferred)/Refrigerated
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. Hereditary Renal Genetic Testing Patient Information (T918)
3. If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.
Useful For
Providing a genetic evaluation for patients with a personal or family history suggestive of Alport syndrome
Establishing a diagnosis of Alport syndrome
Special Instructions
Method Name
Sequence Capture Next-Generation Sequencing (NGS)/Sanger Sequencing
Reporting Name
Alport Syndrome Gene PanelSpecimen Type
VariesSpecimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Varies |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
Alport syndrome (AS) is a genetic disorder characterized by kidney disease, sensorineural hearing loss, and ocular findings. The disease spectrum, severity, and progression are variable; in many cases, kidney disease progresses to kidney failure.(1)
The genes associated with AS form the collagen IV alpha 345 network of basement membranes and have 3 different modes of inheritance. Disease-causing variants in the COL4A5 gene cause X-linked AS (XLAS) and account for approximately two thirds of disease.(1) In hemizygous male patients, XLAS tends to be more severe, while heterozygous female patients typically have a milder presentation (usually only hematuria).(2)
Autosomal recessive AS (ARAS) accounts for approximately 15% of cases and is caused by biallelic disease-causing variants in COL4A3 or COL4A4.(3) Some carriers of ARAS may develop thin basement membrane nephropathy. Digenic inheritance with disease-causing variants in both COL4A3 and COL4A4 has also been reported.(4) Autosomal dominant AS, caused by heterozygous disease-causing variants in COL4A3 or COL4A4, accounts for approximately 20% of cases and tends to exhibit slower disease progression (1,5)
Large deletions that span the adjacent 5' ends of COL4A5 and COL4A6 are associated with a contiguous gene syndrome characterized by AS and diffuse leiomyomatosis in the esophagus, however, disease-causing COL4A6 variants do not appear to be associated with isolated Alport syndrome.(6)
Reference Values
An interpretive report will be provided.
Day(s) Performed
Varies
Report Available
28 to 42 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81407
81408 x 2
81479 (if appropriate for government payers)